Loading…
Clindamycin in the treatment of streptococcal and staphylococcal toxic shock syndromes
OBJECTIVE: To evaluate the utility of clindamycin in the treatment of streptococcal and staphylococcal toxic shock syndromes. DATA SOURCES: Biomedical literature was accessed through MEDLINE (1966–December 1999). Key terms included clindamycin, streptococcal toxic shock, and staphylococcal toxic sho...
Saved in:
| Published in: | The Annals of pharmacotherapy 2000-07, Vol.34 (7), p.936-939 |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c371t-2e4e7b5007156d0af7baf668d35a602332f500ae83a82b38cf646ba0a1553e683 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c371t-2e4e7b5007156d0af7baf668d35a602332f500ae83a82b38cf646ba0a1553e683 |
| container_end_page | 939 |
| container_issue | 7 |
| container_start_page | 936 |
| container_title | The Annals of pharmacotherapy |
| container_volume | 34 |
| creator | Russell, NE Pachorek, RE |
| description | OBJECTIVE:
To evaluate the utility of clindamycin in the treatment of streptococcal and staphylococcal toxic shock syndromes.
DATA SOURCES:
Biomedical literature was accessed through MEDLINE (1966–December 1999). Key terms included clindamycin, streptococcal toxic shock, and staphylococcal toxic shock.
DATA SYNTHESIS:
Streptococcal and staphylococcal toxic shock syndromes are associated with a high mortality rate. β-Lactams have been considered the drug of choice for the treatment of these serious infections, with the occasional use of adjunctive clindamycin, although no clinical evidence has been published to support this latter regimen. An evaluation of the information to propose the usefulness of clindamycin was conducted.
CONCLUSIONS:
Experimental laboratory evidence suggests utility of the adjunctive use of clindamycin in streptococcal and staphylococcal infections complicated by toxin production. Research using animal models comparing clindamycin plus β-lactams with β-lactams alone for the treatment of these infections would be useful. |
| doi_str_mv | 10.1345/aph.19095 |
| format | article |
| fullrecord | <record><control><sourceid>sage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1345_aph_19095</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1345_aph.19095</sage_id><sourcerecordid>10.1345_aph.19095</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-2e4e7b5007156d0af7baf668d35a602332f500ae83a82b38cf646ba0a1553e683</originalsourceid><addsrcrecordid>eNptkEtLxDAUhYMojo4u_APShQouOt48mrZLGXzBgBt1G27TdNqxjyHpUOffG-2ILoQLuTn5uCf3EHJGYUa5iG5wXc5oCmm0R45oJFgoWQz7vgcJIbAEJuTYuRUApJSlh2RCIWWJgPiIvM3rqs2x2eqqDXz1pQl6a7BvTNsHXRE4f1v3ne60xjrANveK99vWP1LffVQ6cGWn3wO3bXPbNcadkIMCa2dOd-eUvN7fvcwfw8Xzw9P8dhFqHtM-ZEaYOIsAYhrJHLCIMyykTHIeoQTGOSv8I5qEY8IynuhCCpkhII0ibmTCp-R6nKtt55w1hVrbqkG7VRTUVzbK_1V9Z-PZ85Fdb7LG5H_IMQwPXOwAdH6zwmKrK_fLCZGmIDx2NWIOl0atuo1t_Yr_Gl6OYFkty6GyRrkG69rbUzUMAxcqVimX_BMTToYm</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Clindamycin in the treatment of streptococcal and staphylococcal toxic shock syndromes</title><source>SAGE</source><creator>Russell, NE ; Pachorek, RE</creator><creatorcontrib>Russell, NE ; Pachorek, RE</creatorcontrib><description>OBJECTIVE:
To evaluate the utility of clindamycin in the treatment of streptococcal and staphylococcal toxic shock syndromes.
DATA SOURCES:
Biomedical literature was accessed through MEDLINE (1966–December 1999). Key terms included clindamycin, streptococcal toxic shock, and staphylococcal toxic shock.
DATA SYNTHESIS:
Streptococcal and staphylococcal toxic shock syndromes are associated with a high mortality rate. β-Lactams have been considered the drug of choice for the treatment of these serious infections, with the occasional use of adjunctive clindamycin, although no clinical evidence has been published to support this latter regimen. An evaluation of the information to propose the usefulness of clindamycin was conducted.
CONCLUSIONS:
Experimental laboratory evidence suggests utility of the adjunctive use of clindamycin in streptococcal and staphylococcal infections complicated by toxin production. Research using animal models comparing clindamycin plus β-lactams with β-lactams alone for the treatment of these infections would be useful.</description><identifier>ISSN: 1060-0280</identifier><identifier>EISSN: 1542-6270</identifier><identifier>DOI: 10.1345/aph.19095</identifier><identifier>PMID: 10928407</identifier><identifier>CODEN: APHRER</identifier><language>eng</language><publisher>Cincinnati, OH: Harvey Whitney Books</publisher><subject>Animals ; Anti-Bacterial Agents - therapeutic use ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Clindamycin - therapeutic use ; Disease Models, Animal ; Drug Therapy, Combination - therapeutic use ; Humans ; Medical sciences ; Pharmacology. Drug treatments ; Shock, Septic - drug therapy ; Shock, Septic - microbiology ; Shock, Septic - mortality ; Staphylococcal Infections - drug therapy ; Streptococcal Infections - drug therapy</subject><ispartof>The Annals of pharmacotherapy, 2000-07, Vol.34 (7), p.936-939</ispartof><rights>2000 SAGE Publications</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-2e4e7b5007156d0af7baf668d35a602332f500ae83a82b38cf646ba0a1553e683</citedby><cites>FETCH-LOGICAL-c371t-2e4e7b5007156d0af7baf668d35a602332f500ae83a82b38cf646ba0a1553e683</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,79364</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1449904$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10928407$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Russell, NE</creatorcontrib><creatorcontrib>Pachorek, RE</creatorcontrib><title>Clindamycin in the treatment of streptococcal and staphylococcal toxic shock syndromes</title><title>The Annals of pharmacotherapy</title><addtitle>Ann Pharmacother</addtitle><description>OBJECTIVE:
To evaluate the utility of clindamycin in the treatment of streptococcal and staphylococcal toxic shock syndromes.
DATA SOURCES:
Biomedical literature was accessed through MEDLINE (1966–December 1999). Key terms included clindamycin, streptococcal toxic shock, and staphylococcal toxic shock.
DATA SYNTHESIS:
Streptococcal and staphylococcal toxic shock syndromes are associated with a high mortality rate. β-Lactams have been considered the drug of choice for the treatment of these serious infections, with the occasional use of adjunctive clindamycin, although no clinical evidence has been published to support this latter regimen. An evaluation of the information to propose the usefulness of clindamycin was conducted.
CONCLUSIONS:
Experimental laboratory evidence suggests utility of the adjunctive use of clindamycin in streptococcal and staphylococcal infections complicated by toxin production. Research using animal models comparing clindamycin plus β-lactams with β-lactams alone for the treatment of these infections would be useful.</description><subject>Animals</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Clindamycin - therapeutic use</subject><subject>Disease Models, Animal</subject><subject>Drug Therapy, Combination - therapeutic use</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Shock, Septic - drug therapy</subject><subject>Shock, Septic - microbiology</subject><subject>Shock, Septic - mortality</subject><subject>Staphylococcal Infections - drug therapy</subject><subject>Streptococcal Infections - drug therapy</subject><issn>1060-0280</issn><issn>1542-6270</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNptkEtLxDAUhYMojo4u_APShQouOt48mrZLGXzBgBt1G27TdNqxjyHpUOffG-2ILoQLuTn5uCf3EHJGYUa5iG5wXc5oCmm0R45oJFgoWQz7vgcJIbAEJuTYuRUApJSlh2RCIWWJgPiIvM3rqs2x2eqqDXz1pQl6a7BvTNsHXRE4f1v3ne60xjrANveK99vWP1LffVQ6cGWn3wO3bXPbNcadkIMCa2dOd-eUvN7fvcwfw8Xzw9P8dhFqHtM-ZEaYOIsAYhrJHLCIMyykTHIeoQTGOSv8I5qEY8IynuhCCpkhII0ibmTCp-R6nKtt55w1hVrbqkG7VRTUVzbK_1V9Z-PZ85Fdb7LG5H_IMQwPXOwAdH6zwmKrK_fLCZGmIDx2NWIOl0atuo1t_Yr_Gl6OYFkty6GyRrkG69rbUzUMAxcqVimX_BMTToYm</recordid><startdate>20000701</startdate><enddate>20000701</enddate><creator>Russell, NE</creator><creator>Pachorek, RE</creator><general>Harvey Whitney Books</general><general>SAGE Publications</general><general>Whitney</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20000701</creationdate><title>Clindamycin in the treatment of streptococcal and staphylococcal toxic shock syndromes</title><author>Russell, NE ; Pachorek, RE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-2e4e7b5007156d0af7baf668d35a602332f500ae83a82b38cf646ba0a1553e683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Animals</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Clindamycin - therapeutic use</topic><topic>Disease Models, Animal</topic><topic>Drug Therapy, Combination - therapeutic use</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Shock, Septic - drug therapy</topic><topic>Shock, Septic - microbiology</topic><topic>Shock, Septic - mortality</topic><topic>Staphylococcal Infections - drug therapy</topic><topic>Streptococcal Infections - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Russell, NE</creatorcontrib><creatorcontrib>Pachorek, RE</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>The Annals of pharmacotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Russell, NE</au><au>Pachorek, RE</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clindamycin in the treatment of streptococcal and staphylococcal toxic shock syndromes</atitle><jtitle>The Annals of pharmacotherapy</jtitle><addtitle>Ann Pharmacother</addtitle><date>2000-07-01</date><risdate>2000</risdate><volume>34</volume><issue>7</issue><spage>936</spage><epage>939</epage><pages>936-939</pages><issn>1060-0280</issn><eissn>1542-6270</eissn><coden>APHRER</coden><abstract>OBJECTIVE:
To evaluate the utility of clindamycin in the treatment of streptococcal and staphylococcal toxic shock syndromes.
DATA SOURCES:
Biomedical literature was accessed through MEDLINE (1966–December 1999). Key terms included clindamycin, streptococcal toxic shock, and staphylococcal toxic shock.
DATA SYNTHESIS:
Streptococcal and staphylococcal toxic shock syndromes are associated with a high mortality rate. β-Lactams have been considered the drug of choice for the treatment of these serious infections, with the occasional use of adjunctive clindamycin, although no clinical evidence has been published to support this latter regimen. An evaluation of the information to propose the usefulness of clindamycin was conducted.
CONCLUSIONS:
Experimental laboratory evidence suggests utility of the adjunctive use of clindamycin in streptococcal and staphylococcal infections complicated by toxin production. Research using animal models comparing clindamycin plus β-lactams with β-lactams alone for the treatment of these infections would be useful.</abstract><cop>Cincinnati, OH</cop><pub>Harvey Whitney Books</pub><pmid>10928407</pmid><doi>10.1345/aph.19095</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1060-0280 |
| ispartof | The Annals of pharmacotherapy, 2000-07, Vol.34 (7), p.936-939 |
| issn | 1060-0280 1542-6270 |
| language | eng |
| recordid | cdi_crossref_primary_10_1345_aph_19095 |
| source | SAGE |
| subjects | Animals Anti-Bacterial Agents - therapeutic use Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences Clindamycin - therapeutic use Disease Models, Animal Drug Therapy, Combination - therapeutic use Humans Medical sciences Pharmacology. Drug treatments Shock, Septic - drug therapy Shock, Septic - microbiology Shock, Septic - mortality Staphylococcal Infections - drug therapy Streptococcal Infections - drug therapy |
| title | Clindamycin in the treatment of streptococcal and staphylococcal toxic shock syndromes |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T17%3A42%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clindamycin%20in%20the%20treatment%20of%20streptococcal%20and%20staphylococcal%20toxic%20shock%20syndromes&rft.jtitle=The%20Annals%20of%20pharmacotherapy&rft.au=Russell,%20NE&rft.date=2000-07-01&rft.volume=34&rft.issue=7&rft.spage=936&rft.epage=939&rft.pages=936-939&rft.issn=1060-0280&rft.eissn=1542-6270&rft.coden=APHRER&rft_id=info:doi/10.1345/aph.19095&rft_dat=%3Csage_cross%3E10.1345_aph.19095%3C/sage_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c371t-2e4e7b5007156d0af7baf668d35a602332f500ae83a82b38cf646ba0a1553e683%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/10928407&rft_sage_id=10.1345_aph.19095&rfr_iscdi=true |